|Glycostem Therapeutics BV, of Oss, the Netherlands||Onkord||Allogeneic natural killer cell immunotherapy||Acute myeloid leukemia||Opened the Wink study testing Onkord in 33 patients who are in complete morphologic remission with residual measurable disease and with no strong indication for hematopoietic stem cell transplantation; primary efficacy endpoint is cumulative incidence of minimal residual disease|
|Inovio Pharmaceuticals Inc., of Plymouth Meeting, Pa.||INO-5401 and INO-9012||DNA-based vaccine expressing antigens for hTERT, WT1 and PSMA and a DNA medicine encoding IL-12||Newly diagnosed glioblastoma||INO-5401 + INO-9012 with Libtayo (cemiplimab, Regeneron Pharmaceuticals Inc.), radiation and temozolomide produced an 18-month survival of 70% in 20 patients with MGMT promoter methylated and 50% in 32 MGMT promoter unmethylated patients; median overall survival for unmethylated GBM patients was 17.9 months; median OS for methylated patients has not yet been reached|
|Clear Creek Bio Inc., of Cambridge, Mass.||Brequinar||Oral DHODH inhibitor||COVID-19||The first patient was dosed in the CRISIS2 study, a randomized, open label, multicenter experiment that will enroll up to 100 non-hospitalized patients who have a positive SARS-CoV-2 test and are symptomatic; participants will receive the current standard of care and be treated once daily for 5 days with either brequinar or a placebo|
|Amarin Corporation plc., of Dublin, and Edding Group Co. Ltd., of Shanghai||Vascepa (icosapent ethyl)||Fish oil||Hypertriglyceridemia||In the EDPC003R01 study in China, Vascepa reduced triglycerides by 19.9% compared to placebo after 12 weeks of treatment (p<0.001)|
|Redhill Biopharma Ltd., of Tel Aviv, Israel||RHB-204||Fixed-dose combination of clarithromycin, rifabutin and clofazimine||Pulmonary nontuberculous mycobacteria||Started the study comparing RHB-204 to placebo in up to 125 patients; endpoints include sputum culture conversion after month 6 of treatment and patient-reported outcomes, including improvements in physical functioning, respiratory symptoms and fatigue|
|Marinomed Biotech AG, of Vienna, Australia||Carragelose (iota-carrageenan)||Sulfated polymer from red seaweed||COVID-19 prophylaxis||Plans to start a 12-week study in 334 health care professionals who are managing COVID-19 patients|
For more information about individual companies and/or products, see Cortellis.